$SBFG

Best Value Stock to Buy for Nov. 21st

SBFG, THFF and TDC made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 21, 2025.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 21, 2025, 11:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 22, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Best Value Stock to Buy for Nov. 21st — source image
Decision brief

The 30-second read

$SBFGBullishMed
01

Why it matters

The focus on stocks with high Zacks Rank and favorable sentiment suggests a short-term bullish bias, especially for SBFG.

02

Market read

The stocks discussed are relevant for value investors and traders focusing on regional financial institutions and healthcare sectors.

03

What to watch

Potential overvaluation or upcoming earnings reports that could influence stock performance.

Timing: Immediate to short-term (next 1-2 weeks)

Background

The article highlights stocks with strong value characteristics and positive analyst ratings, aiming to identify investment opportunities for November 21, 2025.

Company-level read

Ticker impact

$SBFGBullishHigh confidence
Context

High relevance due to strong buy rating and positive sentiment.

Expected impact

Expected moderate price increase of approximately 5-8% over the next 1-3 months.

Evidence & confidence

The stock's Zacks Rank #1 and positive sentiment suggest strong buying momentum, supported by favorable valuation metrics.

$TDCNeutralMedium confidence
Context

Moderate relevance with neutral sentiment, indicating limited immediate trading impact.

Expected impact

Potential for minimal price movement, approximately 1-3%, with increased volatility.

Evidence & confidence

Neutral sentiment tempers aggressive trading; further technical analysis needed for precise timing.

$THFFNeutralMedium confidence
Context

Moderate relevance with neutral sentiment, similar to TDC.

Expected impact

Likely negligible price change, within 1%, with possible sideways movement.

Evidence & confidence

Neutral sentiment indicates uncertainty; technical levels should be monitored.

Market effects

Positive impact on the financial sector, especially regional banks and financial services.

Potential uplift in regional banking stocks, with increased investor interest.

Limited; primarily regional and sector-specific effects.

Counterpoint

The strong buy ratings may be overly optimistic; macroeconomic headwinds or sector-specific risks could limit upside.

Key entities

  • SBFG

    Small Business Financial Corporation, a regional bank with strong valuation metrics.

  • TDC

    Tandem Diabetes Care, a medical device company with neutral outlook.

  • THFF

    First Financial Corporation, a regional bank with neutral sentiment.

Related articles

$TDCMed

Why Is Teradata Stock Falling on Wednesday? - Teradata (NYSE:TDC)

Teradata (TDC) reported Q2 adjusted EPS of 69 cents, above the 56-cent estimate, and sales of $410 million versus $397.1 million expected. For Q3, it guided adjusted EPS of 55 to 59 cents and sales of $391.0 to $399.4 million, both below estimates. FY2026 adjusted EPS was raised to $2.65-$2.73. Barclays cut its price forecast to $27. Shares fell 21.2% to $27.11.

$TDCHighAI 9/10

Teradata (TDC) Stock Trades Down, Here Is Why

Teradata (NYSE: TDC) shares fell 21.5% after the company issued a weaker-than-expected Q3 outlook. Teradata guided for about a 5% year-on-year sales decline and lower EPS than analysts expected, despite Q2 results of $410 million revenue and adjusted EPS of $0.69 beating forecasts.

$TDCHighAI 9/10

Why is Teradata stock tumbling today?

Teradata (TDC) shares fell about 14% pre-open to $29.62 after Q3 guidance missed expectations. Management forecast Q3 2026 recurring revenue down 4% to 2% YoY, total revenue down 6% to 4%, and non-GAAP EPS $0.55 to $0.59 versus $0.62 consensus. Q2 adjusted EPS and revenue beat; full-year EPS raised to $2.65–$2.73. Analysts cut targets.